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The β-galactoside-binding protein, galectin-3, is extensively involved in cancer development, 
progression and metastasis through multiple mechanisms. Inhibition of the galectin-3-
mediated actions is increasingly considered as a promising therapeutic approach for cancer 
treatment. Our early studies have identified several novel galectin-3 binding inhibitors from 
chemical modification of the anticoagulant drug heparin. These heparin-derived galectin-3 
binding inhibitors, which show no anticoagulant activity and bind to the galectin-3 canonical 
carbohydrate-binding site, induce galectin-3 conformational changes and inhibit galectin-3-
mediated cancer cell adhesion, invasion and angiogenesis in vitro and reduce metastasis in 
mice. In this study, we determined the binding affinities of these heparin-derived ligands to 
galectin-3 using an isothermal titration calorimetry (ITC) ligand displacement approach. Such 
ITC experiments showed that the 2-de-O-sulfated, N-acetylated (compound E) and 6-de-O-
sulfated, N-acetylated (F) heparin-derived ligands and their ultra-low molecular weight sub-
fractions (E3 and F3) bind to galectin-3 with KD ranging from 0.96 to 1.32 mM range. 
Differential scanning fluorimetry analysis revealed that, in contrast to the disaccharide ligand, 
N-acetyl-lactosamine, which binds to the fully folded form of galectin-3 and promotes 
galectin-3 thermal stability, the heparin-derived ligands preferentially bind to the unfolded 
state of galectin-3 and cause destabilization of the galectin-3 protein structure. These results 
provide molecular insights into the interaction of galectin-3 with the heparin-derived ligands 
and explain the previously demonstrated in vitro and in vivo effects of these binding 






Galectin-3 is a unique chimera type member of the mammalian β-galactoside-binding 
galectin family. Galectin-3 recognises and interacts with various galactose-terminated 
glycans through a highly conserved carbohydrate-recognition domain (CRD) of 
approximately 130 amino acids arranged into a globular β-sandwich structure [1]. Galectin-3 
also possesses a flexible N-terminal domain composed of a short N-terminal sequence of 
approximately 21 amino acids and a structurally aperiodic collagen-like tail of about 91 
residues[2].  This unique N-terminal domain of galectin-3, which do not occur in other 
galectin members, is required for galectin-3 multimerization in the presence of ligands to 
confer its multivalent properties [3]. Galectin-3 is commonly overexpressed in most types of 
cancers [4, 5]. There is mounting evidence showing that overexpression of galectin-3 has a 
profound impact on cancer development, progression and metastasis via multiple 
mechanisms[6]  These include promoting cancer cell adhesion, invasion, angiogenesis, 
immune suppression and metastasis by its interactions with a number of cell surface, extra- 
and intra-cellular proteins via protein-carbohydrate [7, 8] or protein-protein interactions [9].  
 
The broad effects of galectin-3 on cancer progression and metastasis in wide range of cancer 
types have stimulated substantial interest of research laboratories and biotech companies to 
explore the use of galectin-3-targeting agents for cancer treatment. These agents include: 
Thomsen-Friedenreich antigen-mimicking molecules [10], truncated galectin-3 forms [11], 
peptide-based synthetic inhibitors [12, 13] as well as small carbohydrate-based inhibitors 
such as thiodigalactoside derivatives [14, 15] and allyl lactoside [16]. In addition, multivalent 
carbohydrate-based inhibitors from modified citrus pectin (MCP) and a rhamnogalacturonan-




Heparin is a highly sulphated, heterogeneous polymer glycosaminoglycan with molecular 
weight ranging from 3 to 30 kDa. The predominant heparin disaccharide unit is composed of 
2-O-sulphated iduronic acid and 6-O-sulphated, N-sulphated glucosamine, IdoA(2S)-
GlcNS(6S), with some N-sulphation substituted by N-acetylation [18]. Heparin is a well-
known anticoagulant and antithrombotic agent and is often used to treat cancer-associated 
thromboembolism in cancer patients [19]. Our recent studies have identified several 
chemically modified heparin derivatives as potent galectin-3 binding inhibitors [20]. These 2-
de-O-sulfated, N-acetylated (compound E) and 6-de-O-sulfated, N-acetylated (compound F) 
heparin derivatives were produced by selective desulphation and depolymerisation from 
standard heparin [20]. These chemically modified heparin derivatives and their ultra-low 
molecular weight sub-fractions (<3 kDa) (E3 and F3) show no anticoagulant activity, bind to 
the galectin-3 CRD domain and inhibit galectin-3-mediated cancer cell adhesion, invasion, 
angiogenesis in vitro and reduces metastasis in vivo [20]. These heparin-derived galectin-3 
binding inhibitors are therefore good candidates to be developed as galectin-3-targeting 
therapeutic agents for cancer treatment.  
 
In this study, we determined the binding affinities of these heparin-derived inhibitors to 
galectin-3 using an isothermal titration calorimetry (ITC) competition (ligand displacement) 
approach. We also investigated the binding characteristics of galectin-3 with these novel 
binding inhibitors by differential scanning fluorimetry (DSF) and compared their binding 
with a common disaccharide binding ligand, N-acetyl-D-lactosamine (LacNAc). Our 
investigation revealed some unusual features of interactions of these heparin-derived ligands 




Materials and methods  
Production of chemically modified heparin derivatives 
The two chemically modified heparin derivatives, E and F and their ultra-low molecular 
weight fractions, E3 and F3, were prepared as previously described [18, 20]. 
 
Production of full length and C-terminally truncated recombinant human galectin-3  
The full-length human galectin-3 (Gal-3, residues 1-250) and a C-terminally truncated 
galectin-3 form Gal-3C (residues 115-250) were produced in E.coli as previously described 
[8, 20]. 
 
ITC ligand displacement analysis 
All experiments were performed at 250C using an MICROCAL iTC200 Microcalorimeter 
(Malvern) with 200 µl cell capacity and 40 µl injection syringe volume. For the reference 
run, Gal-3 at 100 µM in the sample cell was titrated with 2 mM LacNAc. To determine the 
KD values for the four heparin-derived ligands, galectin-3 at 100 µM was incubated for 20 
minutes with three different concentrations of the heparin derivatives (0.5, 1 and 2 mM) 
before 2 mM LacNAc was injected into the Gal-3-heparin derivative complex solution. All 
experiments were performed in PBS pH 7.4. LacNAc titration into buffer alone and heparin 
derivative solutions as well as buffer titration into galectin-3 alone were performed in control. 
All the control experiments exhibited undetectable heat exchange confirming appropriate 
buffer match and lack of dilution effect. All the ligands were tested at several concentrations 
to obtain a range of KD
app values. KD values for galectin-3-ligand interactions obtained by 
displacement of LacNAc were determined using the equation:  
KD
app 
=KD+ [[KD / Ki ][L]] where: KDapp
 is the apparent KD for the galectin-3 and LacNAc 
interactions in the presence of a heparin derivative, KD is the KD value for galectin-3-LacNAc 
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interactions in the absence of a heparin derivative, Ki is inhibitory KD which represents the 
true KD value for the galectin-3-heparin derivative interactions and [L] is the concentration of 
the heparin derivative. Ki is calculated from KD
app determined at different heparin-derivatives 
concentrations [L] [21]. Two independent ITC runs were carried out for each ligand. 
 
DSF analysis  
Galectin-3 or Gal-3C at 10 or 20 µM was mixed with LacNAc or heparin derivative at 
several different concentrations. SYPRO Orange (1:400 dilution) was added and the reaction 
volume was topped up with buffer to a total of 75 µl. Twenty-five µl reactions were then 
transferred in triplicates into the wells of a MicroAmp Fast Optical 96-well reaction plate. 
The plate was inserted into StepOne Real Time qPCR. The “Melt Curve” option was selected 
and the thermal denaturation was analysed with the following settings: initial temperature 
equilibration step at 250C for 1 min, followed by gradual increase in the temperature by 0.30C 
up to 950C. LacNAc and the heparin derivatives were also tested without the presence of 
galectin-3 to confirm the lack of interactions between the ligands and the dye. The data was 
analysed using TmTool v1.0 to derive melting temperature and Boltzmann constants. Three 






Analysis of galectin-3 interactions with the heparin-derived ligands using ITC ligand 
displacement  
ITC is the gold standard method for studying protein-ligand interactions. It measures the heat 
generated or absorbed during molecular interactions. Our early study indicated that the 
interaction between galectin-3 and the heparin-derived ligand F3 are relatively weak [22], 
hence making it difficult to achieve the high concentrations of both the ligand and the 
proteins required to obtain a reliable binding isotherm by direct ITC analysis. To obtain more 
accurate measurements of galectin-3 interaction with all the heparin derived binding ligands, 
we employed an ITC ligand displacement approach in this study and analysed galectin-3 
interaction with each of these polysaccharide-based galectin-3 binding ligands.   
 
The disaccharide LacNAc is a well-known galectin-3 ligand. LacNAc and the heparin-
derived ligands all bind to the galectin-3 canonical carbohydrate-binding site within the 
galectin-3 CRD but more galectin-3 amino acid residues have shown to be involved in 
interaction with the heparin derivative ligands than with LacNAc in our early study [20]. In 
this ligand displacement analysis, LacNAc was used as a reference ligand to galectin-3 for 
binding competition with the heparin-derived inhibitors. Galectin-3 at 100 µM was mixed 
and incubated without or with heparin derivative E, F, E3 or F3 at 0 µM, 500 µM, 1 mM and 
2 mM before the Gal-3-heparin derivative solution was titrated with 2 mM LacNAc. LacNAc 
alone binds to galectin-3 with a KD of ~ 26.3 ± 0.5 µM (Figs 1 and 2), which is similar to the 
affinities reported previously using ITC and other methods [23-26]. The presence of each of 
the four heparin-derived ligands caused a decrease in LacNAc binding affinity to galectin-3 
in a dose-dependent manner as well as clear reduction in the heat change upon binding (Fig 
1A and C, Fig 2A and C). The estimated KD values of LacNAc binding to galectin-3 
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increased from 26.3 to 64.4 ± 4.0 µM with increasing concentrations of the heparin derivative 
E from 0 to 2 mM (Fig 1A), and from 26.3 to 66.9 ± 7.9 µM with increasing concentrations 
of F (Fig 1C). Overlays of the ITC titration traces of galectin-3-LacNAc interactions in the 
presence of E or F (Fig 1B and D) showed changes in the shape of the fitting curves with 
increasing E and F concentrations, indicating weakening of LacNAc-galectin-3 interactions 
and thus, a competition between LacNAc and the heparin-derived ligands. Analysis of the 
KD
app values obtained from the presence of different concentrations of heparin derivatives 
against the derivative concentrations showed binding of E (Fig 1B) and F (Fig 1D) to 
galectin-3 with KD of 1.32 mM and 1.25 mM, respectively.  
 
The presence of the ultra-low molecular weight sub-fractions of the heparin derivatives E3 
and F3 showed stronger competition with LacNAc for binding to galectin-3 in comparison to 
the unfractionated E and F (Fig 2A and C). The KD values of LacNAc binding to galectin-3 
increased from 26.3 to 67.4 ± 3.5 µM with E3 and from 26.3 to 77.3 ± 8.5 µM in the presence 
of F3 with increasing heparin derivative concentrations. Again, overlays of the ITC traces of 
LacNAc titrations into galectin-3-heparin derivatives complex solutions (Fig 2B and D) show 
clear shallowing of the binding curves, indicating a weaker LacNAc binding to the protein. 
Analysis of the KD
app values, obtained in the presence of different concentrations of E3 and 
F3, against the derivative concentrations allowed determination of the binding affinities for 
E3 (Fig 1B) and F3 (Fig 1D) to be 1.15 mM and 0.96 mM, respectively. The stronger 
competition with LacNAc exhibited by E3 and F3 for binding to galectin-3 than their 
unfractionated counterparts E and F, is in good agreement with the stronger effect of E3 and 
F3, than E and F, on galectin-3-mediated cell adhesion and metastasis in mice observed in our 




Analysis of galectin-3 interactions with the heparin-derived inhibitors by DSF  
Differential Scanning Fluorimetry monitors the unfolding transition of proteins in response to 
change of temperature and can provide insight into the effect of ligand binding on the thermal 
stability of a protein.  
 
In these experiments, we first determined the thermal stability of Gal-3C (20 µM) in the 
presence of different concentrations of LacNAc. Gal-3C alone was observed to have a 
melting temperature (Tm) of 60.4
0C (Fig 3A). Upon the addition of increasing concentrations 
of LacNAc from 0 to 400 µM, the unfolding curves of Gal-3C were, as expected, shifted to 
higher temperatures (Fig 3A). The change in the melting temperature from 60.40C to 61.90C 
in the presence of 400 µM LacNAc (ΔTm = 1.5
0C) (Fig 3F), indicates an increase in the 
thermal stability of galectin-3C upon LacNAc binding.  
 
Gal-3C thermodenaturation was assessed in the presence of the heparin-derived ligands at 
several different E and F concentrations ranging from 0 to 200 µg/ml, and E3 and F3 from 0 
and 100 µM (equivalent to approximately 0-300 µg/ml, assuming their MW= 3000 Da). The 
presence of each of the four heparin derivatives showed an opposite effect to LacNAc on 
Gal-3C thermal stability. In contrast to LacNAc, binding of the heparin derivatives decreased 
Gal-3C melting temperature in a heparin derivative dose-dependent manner (Fig 3B-E). The 
greatest change in Gal-3C Tm among these polysaccharides was caused by F3 (ΔTm of 2.1 
0C) 
and followed by F (ΔTm of 2.0
0C) (Fig 3F and G). E and E3, both caused a reduction in Gal-
3C melting temperatures by 1.5 
0C (Fig 3F and G). These indicate that in contrast to galectin-
3C stabilisation upon LacNAc binding, interactions of the heparin derivatives with galectin-3 




To test whether the destabilization effect of the heparin-derived ligands was not specific to 
the C-terminal domain of galectin-3, we analyzed the impact of those inhibitors on thermal 
stability of the full-length galectin-3. In the absence of a ligand, the full-length galectin-3 
showed a slightly lower melting temperature (Tm=58.8
0C) than the truncated form of Gal-3C 
(Fig 3A and 4A). This reduction in the melting temperature is likely due to the presence of 
the unstructured, collagen-like N-terminal domain in the full-length galectin-3. Similar to 
Gal-3C, the presence of LacNAc induced a dose-dependent thermal stabilization of the full-
length galectin-3 structure indicated by the rise in the Tm. At 800 µM LacNAc binding 
enhanced the galectin-3 melting temperature by 1.90C (Fig 4A and D). The presence of the 
heparin-derived ligands E3 (Fig 4B) and F3 (Fig 4C) again, produced opposite effect to 
LacNAc and induced a decrease in galectin-3 thermal stability with increasing ligand 
concentrations. At the highest tested concentration of 333 µM (approximately 1 mg/ml), E3 
and F3 caused a reduction in galectin-3 Tm by 1.4 







In this study, an ITC-based ligand displacement analysis revealed the binding affinities of the 
heparin-derived inhibitors to galectin-3 at low mM range. In contrast to the binding of 
disaccharide ligand LacNAc to galectin-3, which enhances galectin-3 structure stability, 
binding of the heparin-derived ligands to galectin-3 interestingly showed thermal 
destabilization of the galectin-3 native structure. 
 
It was found in this study that the ultra-low molecular weight sub-fractions E3 and F3 bound 
galectin-3 with higher affinities than their unfractionated counterparts E and F. This agrees 
with the stronger effect of E3 and F3, than E and F, on inhibition of galectin-3-mediated 
activities in vitro and in vivo shown in our previous study [20]. None of the heparin-derived 
inhibitors contains the canonical galectin-3 binding monosaccharide moiety, galactose. Their 
low binding affinities to galectin-3 revealed in this study are, therefore, not very surprising. 
However, these heparin-derived inhibitors are complex long polysaccharides and each can 
potentially bind to multiple galectin-3 molecules. Thus, although, binding of these heparin 
derivatives to galectin-3 is not very strong, the impact of their binding on galectin-3-mediated 
actions could still be very significant in vivo, due in part to their abilities to provide a scaffold 
for binding multiple galectin-3 molecules. The significant effect of these heparin derivatives 
on inhibition of galectin-3-mediated cancer cell adhesion, invasion, angiogenesis and 
metastasis observed with cancer cells and in mice indeed supports this.  
 
DFS analysis in this study showed that binding of these heparin-derived inhibitors to 
galectin-3 induces destabilization of the galectin-3 protein structure, which is different to the 
galectin-3 binding by the disaccharide ligand LacNAc which enhances galectin-3 thermal 
stability. DSF measurements are based on the principle that ligand binding to a protein alters 
12 
 
the protein’s thermal stability and leads to a shift in the midpoint of the unfolding transition 
of the protein. In general, ligand binding causes an increase in the protein thermal stability 
shown by a rise in the protein melting temperature with increasing ligand concentrations. 
Such ligands which bind to the native state of the protein and stabilise the protein structure 
are called N-binders or upshifters. Some ligands preferentially bind to the unfolded state of a 
protein, cause a destabilisation and promote unfolding. This class of ligands, which reduce 
the protein melting temperature in DFS measurements, is called U-binders or downshifters 
[27]. In this study, LacNAc binding to galectin-3 showed a classical binding pattern of N-
binders which increased protein melting temperature with increasing LacNAc concentration. 
In contrast, the heparin-derived inhibitors showed the classical behavior of U-binders that 
reduce the protein melting temperature with increasing ligand concentrations. This indicates 
that the heparin-derived ligands preferentially bind to the partially unfolded state of galectin-
3 and induce thermal destabilization of the galectin-3 structure. The effect of these heparin 
derived ligands on galectin-3 structure destabilization concurs well with our early discovery 
that binding of these heparin-derived inhibitors to galectin-3 induces galectin-3 conformation 
changes as assessed by synchrotron radiation circular dichroism [20].  
 
In this study, an ITC competition (ligand displacement) approach was used to determine the 
dissociation constants of the heparin-derived inhibitors with galectin-3. While direct ITC 
measurements can reliably characterise protein-ligand interactions with binding affinities >1 
nM and <100 μM [28], it often faces challenges in accurate determination of high affinity 
ligand binding with KD in picomolar/low nanomolar range as well as of weak ligand binding 
with KD in mM range. ITC competition approach has been previously used to determine 
dissociation constants of very strong binding ligands [28, 29], in which the association 
constant (KA) for the high affinity ligands is artificially lowered to a measurable level by 
13 
 
introduction of a weaker competitive ligand. In this study, the ITC competition experimental 
mode was successfully applied to measure the dissociation constants of low-affinity 
polysaccharide ligands. This provides support to the effectiveness of using ITC ligand 
displacement approach in determining weak binding ligands which so far has only been 
reported in very few studies [30, 31].  
 
In conclusion, the binding affinity of the heparin-derived inhibitors to galectin-3 is in the low 
mM range. In contrast to LacNAc, which binds to the fully-folded state of galectin-3 and 
enhances galectin-3 protein stability, the heparin-derived inhibitors preferentially bind to the 
partially unfolded state of galectin-3 and destabilize the protein structure. These discoveries 
provide insight into the molecular interaction of galectin-3 with the heparin derivatives. The 
influence of these novel binding ligands on galectin-3 protein stability revealed in this study 
may itself be an independent mechanism of their inhibitory effect on galectin-3-mediated 
cancer cell behaviours shown in vitro and in vivo in our previous studies. The information 
from this study may be useful in future development of these novel binding inhibitors as 
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Figure 1. Analysis of galectin-3 interactions with heparin-derived ligands E and F by 
ITC ligand displacement. Galectin-3 (100 µM) was mixed with 0, 0.5, 1.0 and 2.0 mM E 
(A) or F (C) before titration with 2 mM LacNAc. The integrated ITC data was fitted to a One 
set of sites interaction model and the dissociation constants (KD) were determined. The KD
app 
was plotted against heparin derivative concentration and the KD values for galectin-3 
interactions with E (B) and F (D) were calculated using the equation described in the 
Methods section. Data are expressed as mean ± SD from two independent experiments.  
 
Figure 2. Analysis of galectin-3 interactions with heparin-derived ligands E3 and F3 by 
ITC ligand displacement. Galectin-3 (100 µM) was mixed with 0, 0.5, 1.0 and 2.0 mM E3 
(A) or F3 (C) before titration with 2 mM LacNAc. The integrated ITC data was fitted to a 
One set of sites interaction model and the dissociation constants (KD) were determined. The 
KD
app was plotted against heparin derivative concentration and the KD values for galectin-3 
interactions with E3 (B) and F3 (D) were calculated using the equation described in the 
Methods section. Data are expressed as mean ± SD from two independent experiments.  
 
Figure 3. Investigation of Gal-3C interaction with LacNAc and the heparin-derived 
ligands by DSF.  
Gal-3C thermodenaturation curves in the presence of LacNAc (A), E (B), F (C), E3 (D) and 
F3 (E) at different concentrations were analysed by DSF. A shift of the melting curves to a 
higher temperature with increasing LacNAc concentrations and shifts to lower temperatures 
with increasing heparin derivative concentrations were observed. Panels F and G show the 
magnitude of melting temperature changes for each of the conditions indicated. Data were 
obtained from three independent experiments, each in triplicates. 
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Figure 4. Investigation of full-length galectin-3 interactions with LacNAc and the 
heparin-derived ligands by DSF.  
Galectin-3 thermodenaturation curves in the presence of LacNAc (A), E3 (B) and F3 (C) at 
different concentrations were determined by DSF. A shift of the melting curves to a higher 
temperature with increasing LacNAc concentrations and shifts to lower temperature with 
increased heparin derivative concentrations were observed. Panel D shows the magnitude of 
melting temperature changes for each of the conditions indicated.  Data were obtained from 
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KD= 64.4±4.0 µMKD= 38.8±0.8 µM



















































































































































































E 1mM/LacNAc E 2mM/LacNAc
KD= 1.32 mM























































































































































































































































































































































































































































































































































































1 .21 0 6
1 .41 0 6





















G a l-3 C  2 0  M
G a l-3 C  +  E 3  1  M
G a l-3 C  +  E 3  5  M
G a l-3 C  +  E 3  2 0  M
G a l-3 C  +  E 3  1 0 0  M







1 .21 0 6
1 .41 0 6





















G a l-3 C  2 0  M
G a l-3 C  +  F 3  1  M
G a l-3 C  +  F 3  5  M
G a l-3 C  +  F 3  2 0  M
G a l-3 C  +  F 3  1 0 0  M







1 .21 0 6
1 .41 0 6





















G a l-3 C  2 0  M
G a l-3 C  +  E  1 0  g / m l
G a l-3 C  +  E  2 0  g / m l
G a l-3 C  +  E  1 0 0  g / m l
G a l-3 C  +  E  2 0 0  g / m l







1 .21 0 6
1 .41 0 6





















G a l-3 C  2 0  M
G a l-3 C  +  F  1 0  g / m l
G a l-3 C  +  F  2 0  g / m l
G a l-3 C  +  F  1 0 0  g / m l
G a l-3 C  +  F  2 0 0  g / m l
A B C 
D 







1 .21 0 6






















G a l-3 C
G a l-3 C  +  L a c N A c  2 0  M
G a l-3 C  +  L a c N A c  1 0 0  M
G a l-3 C  +  L a c N A c  2 0 0  M














LacNAc 20 µM, E/F 10 µg/ml
LacNAc 100 µM, E/F 20 µg/ml
LacNAc 200 µM, E/F 100 µg/ml














LacNAc 20 µM, E3/F3 1 µM
LacNAc 100 µM, E3/F3 5 µM
LacNAc 200 µM, E3/F3 20 µM



































G a l-3  +  L a c N A c  5 0  M
G a l-3  +  L a c N A c  1 0 0  M
G a l-3  +  L a c N A c  2 0 0  M
G a l-3  +  L a c N A c  8 0 0  M
G a l-3  +  L a c N A c  4 0 0  M
































G a l-3  +  E 3  2 .5  M
G a l-3  +  E 3  2 5  M
G a l-3  +  E 3  1 0 0  M
G a l-3  +  E 3  1 6 5  M
G a l-3  +  E 3  3 3 3  M
G a l-3  +  E 3  5  M
































G a l-3  +  F 3  2 .5  M
G a l-3  +  F 3  2 5  M
G a l-3  +  F 3  1 0 0  M
G a l-3  +  F 3  1 6 5  M
G a l-3  +  F 3  3 3 3  M


















LacNAc 50 µM, E3/F3 5 µM
LacNAc 100 µM, E3/F3 25 µM
LacNAc 200 µM, E3/F3 100 µM
LacNAc 400 µM, E3/F3 165 µM
LacNAc 800 µM, E3/F3 333 µM
A 
C
B 
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